PSMA Imaging: Current Status & Prospects

Viewing Information

Getting Started

To fully participate in this online program you must be registered and logged in. Read all the information presented below. When ready select the "View Program" tab above.

Claiming CME/CE Credits

To receive CME/CE credits, participants must review the program materials in their entirety and complete the online post examination and evaluation with a score of 75% or better.

System Hardware/Software and Internet Connection Requirements

The following information is provided for your reference in conjunction with review of this program.

General System and Internet Requirements:  Speakers or Headphones, High Speed Internet connection, Wireless 3G and 4G,
Web browsers: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher and Chrome.

Operating Systems:  Windows 2000 or higher, (MS Surface and other MS mobile devices compatible), MAC OSX 10.3 or higher, Mac iOS 5.0 or higher (iPad, iPhone compatible), Android 4.3 or higher (most Android mobile devices compatible).

Program Summary

By ordering diagnostic procedures to determine the next course of treatment, Urologists play an important role in the management and care of the prostate cancer patient. This diagnosis and management can vary based on the availability of the latest technology. PSMA -11 PET-CT can accurately detect prostate cancer spread and offers improved patient outcomes.

This CME accredited Expert Forum Webinar features a panel of experts in their respective areas of medical imaging including; Nuclear Medicine, Urology, and Oncology. Each will share their experiences of the clinical utility of PSMA-11 PET/CT and its impact on patient management; delivering a clear understanding of the benefits of PSMA-11 imaging. Following the webinar, attendees are afforded the opportunity to correspond with the panel members through email to address questions and discuss specific patient needs.

CME Effective Date: October 29, 2020
CME Expiration Date: October 31, 2022

CE Effective Date October 29, 2020
CE Expiration Date: October 31, 2022

Format: Self Instructional - Audio Visual with Slides
Educational Credits:
One (1) AMA/PRA Category 1 CME Credit™
One (1) ARRT Category A CE Credit.
One (1) AHRA CRA Credit
One (1) ANCC Nursing Credit
One (1) SNMMI VOICE Credits (Pending Approval)
Estimated Completion Time: 1 hour

This program is made possible through an unrestricted educational grant from Telix Pharmaceuticals

Target Audience & Cost

This program is intended for: Urologists. Oncologist, Radiologists, Nuclear Medicine, Other MD's, Radiologic Technologists, Radiology Administrators, Nurses and related Healthcare Professionals.

There is no cost to participate in this program.

Educational Objectives

Upon completion of this CME activity the healthcare provider should be able to:

  1. Discuss the clinical benefits of PSMA Imaging for the diagnosis and management of prostate cancer
  2. Describe patient considerations for 68GA PSMA-11 PET/CT
  3. Articulate the clinical implications supporting the timely diagnosis of prostate cancer
  4. Implement guidelines of when to order 68GA PSMA-11 vs other imaging modalities (Bone scan, CT, MRI)
  5. Implement PSMA Imaging practice considerations to improve outcomes and patient management

No special educational preparation is required for this CME/CE Activity!

Presented by

Jeremie Calais, MD, MSc Jeremie Calais, MD, MSc
Clinical Research Director; Assistant Professor
Ahmanson Translational Theranostics Division

Dr. Jeremie Calias' work focuses on improving the outcomes of cancer patients by translating and applying novel diagnostic and therapeutic approaches. He uses Positron Emission Tomography/Computed Tomography (PET/CT) imaging for cancer phenotyping, radiation therapy planning and therapy response assessment. He leads the clinical theranostics research program at UCLA that combines radionuclide therapy and imaging.

Jeffrey Karnes, MD Jeffrey Karnes, MD
Chair, Division of Community Urology
Department of Urology
Mayo Clinic

Dr. Jeffrey Karnes research interests in the area of urology include: prostate cancer outcomes following radical prostatectomy, staging and surgery for advanced prostate cancer (special interest), prostate cancer biomarker discovery and implementation, bladder cancer urine markers, prostate and bladder cancer clinical trials, and active surveillance in prostate cancer.

Oliver Sartor, MD Oliver Sartor, MD
Laborde Professor of Cancer Research
Medical Director, Tulane Cancer Center
Tulane University School of Medicine

Dr. Oliver Sartor returned to Louisiana in 1993 to serve as an Associate Professor at the LSU Medical School in Shreveport and then moved to the LSU Health Sciences Center in New Orleans in 1998 as the Patricia Powers Strong Professor of Oncology, Stanley S. Scott Cancer Center Director, and Hematology/Oncology Section Chief. He was the Co-Director of the Louisiana Cancer Research Consortium, starting at its legislative inception in 2002. In March 2006, he left LSU to join the Lank Center for Genitourinary Oncology at the Dana Farber Cancer Institute and the Harvard Medical School. In January 2008, Dr. Sartor joined Tulane University as the C. E. and Bernadine Laborde Professor of Cancer Research in the Departments of Medicine and Urology. In July 2010, Dr. Sartor was named Medical Director of the Tulane Cancer Center.

Conflict of Interest Disclosure Policy

IAME requires everyone who is in a position to control the content of a CE/CME activity to disclose all relevant financial relationships with any commercial interest. This information is utilized to 1) determine if a conflict exists, 2) resolve the conflict by initiating a content validation process, and 3) advise learners of this information. Any individual who refuses to (or chooses not to) disclose relevant financial relationships will be disqualified from participating as an instructor, planner or manager and cannot have control of or responsibility for the development, management, presentation or evaluation of a CE/CME activity certified by IAME.


Jeremie Calais, MD, MSc,
Progenics (Advisory Board Meeting - June 2020) • GE Healthcare (GalliProst Advisory Board Meeting – May 2020) • Curium (Prostate Cancer Investigational Products Advisory Board – April 2020) • Janssen (Radioconjugate Virtual Advisory Board – December 2019).

Jeffrey Karnes, MD,
Telix (Education Steering Committee) • Gerome Dx (Decipher, Institutional Personal Royalities)

Oliver Sartor, MD,
Advanced Accelerator Applications • Astellas • AstraZeneca • Bayer • Blue Earth Diagnostics, Inc. • Bavarian Nordic • Bristol Myers Squibb • Clarity Pharmaceuticals • Cloivs • Constellation-Dendreon • EMD Serono • Fusion • Janssen-Myovant • Myriad • Noria Therapeutics, Inc. • Novartis • Noxopharm-Progenics • POINT Biopharma • Pfizer • Sanofi • Tenebio • Telix • Theragnostics • Dendreon • Endocyte • Innocrin • Invitae • Merck • SOTIO

No individual at IAME who had control over the content of this program has relationships with FUJIFILM Medical Systems U.S.A., Inc. or any other commercial interest.


The Institute for Advanced Medical Education (IAME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Institute for Advanced Medical Education (IAME) designates this enduring material for a maximum of 1.0 AMA/PRA Category 1 CME Credits.™ Physicians should only claim credit commensurate with the extent of their participation in the activity.

Radiologic Technologists:
This course meets all criteria and has been approved by the AHRA, The Association for Medical Imaging Management for One (1) ARRT Category A CE Credit.

Radiology Administrators:
This course meets all CRA renewal credit criteria and has been approved for One (1) continuing education credit in the following CRA domains: Asset Resource Management (AM) and Operations Management (OM).

The Foundation for Care Management is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. 1 Nursing contact hour.

Nuclear Medicine Technologists:(Pending Approval)
The SNMMI, through its Verification of Involvement in Continuing Education (VOICE) program, has approved this course for a maximum of 1.0 continuing education hours (CEHs). VOICE-approved credit is recognized by most licensure states and by the NMTCB and ARRT as Category A+ credit.

For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board or other credentialing organization.

Method of Participation/Criteria for Success

CME Credits
To receive CME credits for participating in this CME activity you must successfully complete the online post examination with a passing score of 70% or higher.

CE Credits
To receive CE credits for participating in this CE activity you must successfully complete the online post examination with a passing score of 80% or higher.

Online examinations return an immediate grade report. Upon receiving a passing score click Continue and complete the evaluation form. To view and print your Statement of Credit click the Print/View Certificate button displayed from within your MyAR Archives page.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.